Phosphodiesterase 10A inhibitors: a 2009 – 2012 patent update

Abstract

Introduction: Inhibitors of the phosphodiesterase enzyme PDE10A have been the target for extensive investigations and huge drug discovery research efforts during the recent years. Although PDE10A with its 13 years history is a relatively newly discovered target, it has been paradigmatic for the new generation of ‘high efficiency drug discovery’. Several companies now have clinical programs aiming at validating the clinical potential of PDE10A inhibitors. The majority of companies have been focusing on the treatment of schizophrenia since preclinical evidence suggests that a PDE10A inhibitor could provide antipsychotic, pro-cognitive and negative symptom efficacy.

Areas covered: This article highlights and reviews research advances published in the patent literature since mid-2009 until mid-2012. The article is supplemented with selected publications from the scientific literature, emphasizing the possible involvement of PDE10A inhibitors in the treatment of schizophrenia.

Expert opinion: Several compounds from various companies are currently undergoing clinical testing, dominated by compounds in clinical Phase I. Focus is mainly on CNS diseases and schizophrenia is the leading target indication.

Keywords::

• antipsychotic
• basal ganglia
• Huntington's disease
• medium spiny neuron
• negative symptom
• PDE10A
• phosphodiesterase 10A
• pro-cognitive
• schizophrenia
• striatum

Notes

This box summarizes key points contained in the article.